TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Key Inclusion Criteria:~Part 1:~* Participants with genetically confirmed diagnosis of XLRP (with RPGR mutation).~* Participant with active disease clinically visible within the macular region in both eyes.~Part 2:~- Participant with mean total retinal sensitivity in the study eye as assessed by microperimetry ≥ 0.1 dB and ≤8 dB.~Key exclusion Criteria:~Parts 1 and 2:~* Participant with history of amblyopia in either eye.~* Participated in a gene therapy trial previously or a clinical trial with an investigational drug in the past 12 weeks or received a gene/cell-based therapy at any time previously.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: BIIB112 Dose 1 (Type: EXPERIMENTAL): Participants will receive a single Dose 1 of BIIB112 by sub-retinal injection on Day 0.
- Part 1: BIIB112 Dose 2 (Type: EXPERIMENTAL): Participants will receive a single Dose 2 of BIIB112 by sub-retinal injection on Day 0.
- Part 1: BIIB112 Dose 3 (Type: EXPERIMENTAL): Participants will receive a single Dose 3 of BIIB112 by sub-retinal injection on Day 0.
- Part 1: BIIB112 Dose 4 (Type: EXPERIMENTAL): Participants will receive a single Dose 4 of BIIB112 by sub-retinal injection on Day 0.
- Part 1: BIIB112 Dose 5 (Type: EXPERIMENTAL): Participants will receive a single Dose 5 of BIIB112 by sub-retinal injection on Day 0.
- Part 1: BIIB112 Dose 6 (Type: EXPERIMENTAL): Participants will receive a single Dose 6 of BIIB112 by sub-retinal injection on Day 0.
- Part 2: BIIB112 High Dose (Type: EXPERIMENTAL): Participants will receive a single high dose of BIIB112 by sub-retinal injection.
- Part 2: BIIB112 Low Dose (Type: EXPERIMENTAL): Participants will receive a single low dose of BIIB112 by sub-retinal injection.
- Part 2: Untreated Group (Type: NO_INTERVENTION): Participants will receive no intervention to allow for a controlled comparison.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (AD group):~* Probable AD according to the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria~* Mild/moderate dementia as evidenced by a mini mental state exam (MMSE) score ranging from 10 to 24, boundaries included, at screening~* History of cognitive decline had been gradual in onset and progressive over a period of at least 6 months~Inclusion Criteria (healthy volunteer group):~* No evidence of significant cognitive impairment by history and psychometric testing~* MMSE of 29 or higher~Exclusion Criteria (both groups):~* Neurodegenerative disorders other than AD~* Cognitive impairment resulting from trauma, hypoxic damage, vitamin deficiency, brain infection, brain cancer, endocrine disease, or mental retardation~* Clinically significant infarct or possible multi-infarct dementia as defined by the NINCDS criteria~* Evidence on screening MRI or other biomarker that suggests alternate etiology for cognitive deficit (for healthy controls, evidence suggesting the presence of AD pathology)~* Clinically significant psychiatric disease~* History of epilepsy or convulsions~* Clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances~* Current clinically significant cardiovascular disease~* Received investigational medication within the last 30 days

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Subjects With AD (Type: EXPERIMENTAL): Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination (MMSE) from 10 to 24)
- Healthy Elderly Subjects (Type: EXPERIMENTAL): Cognitively normal with MMSE of 29 or higher; age 50 years or older

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Imaging of Pulmonary Nodules by SGM-101

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects over 18 years of age~* Subjects presenting with a lung, pleural nodule or mass presumed to be resectable on pre-operative assessment~* Good operative candidate~* Subject is capable of giving informed consent and participating in the process of consent.~Exclusion Criteria:~* At-risk subject populations:~  1. Homeless subjects~ 2. Subjects with drug or alcohol dependence~ 3. Children and neonates~ 4. Subjects unable to participate in the consent process.~* Female patients should not be pregnant or lactating. Women of child-bearing potential will be included provided that they have a negative pregnancy test or provide documentation of sterilization, menopausal or post-menopausal status, prior to infusion.~* Patients who have received SGM-101 in the past.~* Patients who have received any investigational drug four weeks of the injection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGM-101 (Type: EXPERIMENTAL): SGM-101 (5-10 mg) will be administered intravenously over 30 minutes followed by a 50 mL flush of isotonic saline to account for the dead volume of the tubing. SGM-101 will be administered 3 to 5 days (+/-1 day) prior to surgery. As a prophylactic measure to ensure the possibility of allergic reaction is absolutely minimized, 25 mg of IV Benadryl may be given the subject prior to the infusion of SGM-101 at the discretion of the Principal Investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient presenting with known or highly suspected CNS lesion(s) with focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors) based on results of a previous imaging procedure such as Computed Tomography (CT) or MRI, which should have been performed within 12 months prior to ICF signature.~Exclusion Criteria:~* Patient presenting with acute or chronic renal insufficiency, defined as an estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73 m² assessed within 1 day prior to each contrast agent injection~* Patient presenting extra cranial lesions and/or extra-dural lesions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI (Type: OTHER): cross-over design. each patient will receive gadopiclenol for the first MRI and gadobutrol for the second MRI
- gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI (Type: OTHER): cross-over design. each patient will receive gadobutrol for the first MRI and gadopiclenol for the second MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has at least 1 year history of migraine (with or without aura)~* Females of childbearing years must use acceptable contraception throughout trial~Exclusion Criteria:~* Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)~* Patient has history or evidence of uncontrolled diabetes, or Human Immunodeficiency Virus (HIV) disease. Patient has uncontrolled cardiovascular disease~* Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)~* Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption~* Patient has a history of cancer within the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK0974 50 mg (Type: EXPERIMENTAL): MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack
- MK0974 150 mg (Type: EXPERIMENTAL): MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack
- MK0974 300 mg (Type: EXPERIMENTAL): MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack
- Placebo (Type: PLACEBO_COMPARATOR): Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Dexmedetomidine for Treatment of Shivering During Cesarean Section Under Neuraxial Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cesarean delivery under neuraxial anesthesia (epidural or spinal) planned or unplanned between 8 am and 8 pm on week days when one of the investigator is present.~* Participants with fever or shivering before the cesarean section are include~Exclusion Criteria:~* No comprehension of french or english language~* Urgent cesarean delivery for non reassuring fetal tracing~* Extremely urgent cesarean delivery (grade 1)~* Weight \< 60 kg ou \> 120 kg~* Hypersensibility to dexmedetomidine~* Heart, renal or hepatic disease requiring follow up, medication or with a possibility of instability during cesarean delivery~* Pre-eclampsia~* Combined spinal-epidural anesthesia~* Conversion into general anesthesia~* Blood products transfusions or major complications during surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): Dexmedetomidine 4 mcg/ml, 30 mcg (7,5 ml), single intravenous bolus
- Normal saline (Type: PLACEBO_COMPARATOR): NaCl 0,9% 7,5 ml, single intravenous bolus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female subjects who are ≥18 years of age, on the day of signing informed consent.~* Diagnosis of psoriatic arthritis meeting Classification Criteria for Psoriatic Arthritis (CASPAR)~* Have active psoriatic arthritis defined as ≥5 swollen joints (from a 66 swollen joint count \[SJC\]) and ≥5 tender joints (from a 68 tender joint count \[TJC\]) at Screening and Baseline (measurable dactylitis of a digit counts as a single swollen joint and if tender, then also a single tender joint).~* Have had a history of documented plaque psoriasis or currently active plaque psoriasis~* If using cDMARD therapy, subjects must have been on it for 12 weeks prior to screening, with a stable dose (including stable route of administration) for at least 4 weeks prior to baseline.~* If using non-drug therapies (including physical therapies), thse should be kept sable during screening~* Male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use highly effective methods of contraception as described in the protocol~Key Exclusion Criteria:~* Use of JAK inhibitors, investigational or approved, at any time, including filgotinib;~* Prior use of more than one TNF inhibitor, at any time.~* Use of oral steroids at a dose \>10 mg/day of prednisone or prednisone equivalent or at a dose that hasn't been stable for at least 4 weeks prior to Baseline;~* Any therapy by intra-articular injections (e.g. corticosteroid, hyaluronate) within 4 weeks prior to screening;~* Use of more than 1 NSAID or cyclooxygenase-2 (COX-2) inhibitor.~* Have undergone surgical treatment for psoriatic arthritis including synovectomy and arthroplasty in more than 3 joints and/or within the last 12 weeks prior to screening~* Presence of very poor functional status or unable to perform self-care.~* Administration of a live or attenuated vaccine within 12 weeks prior to baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- filgotinib (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NATO Litter: Fluid Immersion System (FIS) Versus Traditional Mattress for Pressure Dispersion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults over the age of 18 years with lawful access to Travis Air Force Base (AFB)~Exclusion Criteria:~* Orthopedic or neurological conditions that prevent a subject from lying flat (supine) without any pillows for head, neck, or lumbar support~* Medical conditions (such as an uncontrollable tremor or twitch) that prevent a subject from staying still for the required periods of time (20 minute increments).~* Pregnancy~* Inability to ambulate unassisted, unstable gate (presenting increased fall risk)~* Extremity prosthetics (hand/arm or foot/leg)~* Height greater than 72 inches (6 feet) - exceeds length of the litter \& mattress surfaces~* Body weight greater than 300 lbs~* Subjects who find it difficult, uncomfortable or impossible to remain still for the necessary study time durations (20 minute increments) on the relatively narrow litter surfaces will be removed from the study.~* Subject does not speak or understand the English language

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NATO WELP combination (Type: EXPERIMENTAL): Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and WELP mattress combination
- NATO FIS combination (Type: EXPERIMENTAL): Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and Fluid Immersion System (FIS) mattress combination
- RAVEN WELP combination (Type: EXPERIMENTAL): Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and WELP mattress combination
- RAVEN FIS combination (Type: EXPERIMENTAL): Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and Fluid Immersion System (FIS) mattress combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dextroamphetamine and tDCS to Improve the Fluency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18~* Native English proficiency;~* Nonfluent speech;~* Premorbid right handedness;~* Non-hemorrhagic left hemispheric stroke at least 6 months prior to the investigation.~* No contraindications for MRI (only subjects who will undergo MRI scan).~Exclusion Criteria:~* Hypersensitivity or idiosyncrasy to dextroamphetamine or to other sympathomimetic agents;~* Pregnant or trying to become pregnant;~* Active alcohol abuse, illicit drug use or drug abuse or significant mental illness;~* Subjects receiving alpha adrenergic antagonists or agonists;~* Any history of epilepsy;~* Any condition that would prevent the subject from giving voluntary informed consent;~* An implanted brain stimulator;~* Aneurysm clip or other metal in the brain;~* Enrolled or plans to enroll in an interventional trial during this study;~* Scalp wounds or infections;~* Previous stroke with residual deficits (TIAs not a reason for exclusion);~* A concurrent progressive neurologic disorder, acute coronary syndrome, severe heart disease (NYHA Classification \> 3), or other major medical condition;~* Advanced atherosclerosis, Unstable cardiac dysrhythmia or uncontrolled hypertension (\>160/100 mm Hg), or untreated hyperthyroidism;~* Diagnosis of glaucoma~* During or within 14 days following the administration of monoamine oxidase inhibitors;~* Subjects requiring palliative care;~* Terminal medical condition such as AIDS or cancer;~* Subjects unable to comprehend or follow verbal commands;~* Based on PI's or local physician's assessment patient unable to tolerate the trial procedure due to medical condition;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexedrine+sham tDCS+speech therapy (Type: EXPERIMENTAL): 10 mg Dexedrine and speech therapy for 10 days
- active tDCS+placebo+speech therapy (Type: EXPERIMENTAL): 1.5 mA anodal tDCS and speech therapy for 10 days
- Dexedrine+tDCS+speech therapy (Type: EXPERIMENTAL): 10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days
- sham stimulation+placebo+speech therapy (Type: EXPERIMENTAL): Sham stimulation, placebo and speech therapy for 10 days
- Dexedrine+tDCS+Speech Therapy (Type: EXPERIMENTAL): 10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
- placebo+tDCS+Speech Therapy (Type: EXPERIMENTAL): 1.5 mA anodal tDCS, and speech therapy for 1 day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exercise Training Versus Drug Therapy for Treating Depression in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of major depressive disorder (MDD)~* Score of greater than 11 on the Beck Depression Inventory (BDI)~Exclusion Criteria:~* Primary psychiatric diagnosis other than major depressive disorder (e.g., bipolar disorder)~* Any of the following DSM-IV diagnoses: dementia or delirium; obsessive compulsive disorder (OCD); schizophrenia, schizoaffective, or other psychotic disorder; psychotic features, including any delusions or hallucinations during the current depressive episode; current alcohol or other substance abuse disorder; acute risk for suicide (e.g., score of greater than 2 on the suicide item on the HAM-D) or acute risk for homicide~* May require treatment with additional psychotherapeutic agents (other than chloral hydrate for sleep) during the course of the study~* Significant medical conditions that may cause an increased risk for a significant adverse experience during the course of the trial (e.g., unstable angina, myocardial infarction within 3 months of study entry, etc.)~* Unable to be randomly assigned to the study drug due to a risk for adverse cardiac events, such as prolonged QT interval, use of other medications that would be counterindicated for use with sertraline, or other conditions that may make study participation unsafe~* Unable to be randomly assigned to an exercise condition due to medical conditions such as musculoskeletal problems or abnormal cardiac response to exercise (e.g., exercise-induced ventricular tachycardia, abnormal blood pressure response, etc.)~* Currently receiving antidepressant medication or actively engaged in psychotherapy~* Currently exercising regularly

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete